- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03675139
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients pathologically diagnosed with nonatypical simple or complex EH will be enrolled. Exclusion criteria include malignancy, liver disease or liver tumor (benign or malignant), kidney disease or kidney tumor (benign or malignant), any contradictions against progesterone, history of endometrial atypical hyperplasia or endometrial cancer, any progesterone-dependent tumors, ask for other treatment.
A detailed history including menstruation, fertility, other diseases and family history will be collected. Basic information including age, waist circumstances, hip circumstances and blood pressure will also be collected. Blood tests including fasting blood glucose (FBG), postprandial blood glucose (PBG), fasting insulin (FINS), SHBG, sex hormone levels, blood lipids, liver and kidney functions will be performed before taking progesterone orally.
All enrolled and consent informed patients will be randomized into two groups, A and B, using computer-generated random numbers. Patients in group A will orally take MPA (Medroxyprogesterone Acetate) (angonghuangtitong, Xianju pharmaceuticals, China)10mg daily from tenth day of menstruation for 15 days for 3-6months. While patients in group B will take dydrogesterone (duphaston; Abbott Healthcare Products B.V, the Netherlands) 10 mg, 2 tablets twice daily from fifth day of menstruation for 20 days for 3-6 months. Endometrial Biopsy (Pipelle) will be performed every 3 months to examine the endometrium.
Complete response (CR) is defined as the reversion of EH to proliferative or secretory endometrium; partial response (PR) is defined as regression to disordered proliferative endometrium (DPE) or simple hyperplasia without atypic (only for complex hyperplasia); no response (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as the progression of endometrial lesions.
Another 3-month therapy will be continued if the patients get NR. The longest treatment periods will be 6 months. If the patient gets PD or NR after 6 months therapy, new options must be put.
At least 3-month maintenance therapy will be recommended for patients get CR. And all of the enrolled patients will be followed up for 2 years. All data of the therapy, reverse events, side effects, pregnancy and long-term outcomes will be collected.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Weiwei Shan, PhD
- Phone Number: 862163455050
- Email: fdsww1024@sina.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200011
- Obstetrics and Gynecology Hospital, Fudan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically confirmed diagnosis of endometrial hyperplasia without atypia;
- Consent informed and signed;
- Able to follow treatment and take therapy in Obstetrics and Gynecology of Fudan University
Exclusion Criteria:
- Liver disease or liver tumor (benign or malignant)
- Kidney disease or kidney tumor (benign or malignant)
- Other malignancies in reproductive organs
- Breast cancer or other progesterone-dependent tumors
- History of endometrial atypical hyperplasia or endometrial cancer
- Any contradictions against progesterone
- Under treatment of progestin therapy or oral conceptive drugs one month before enrollment.
- Pregnancy or suspicion of pregnancy
- Ask for other treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Medroxyprogesterone Acetate
EH patients will take MPA (Medroxyprogesterone Acetate) 10mg daily from tenth day of menstruation for 15 days for 3months.
Endometrial Biopsy (Pipelle) will be performed every 3 months to examine the endometrium.
All of the findings will be recorded.
|
At a dosage of 10mg/day
Other Names:
|
Experimental: dydrogesterone
EH patients will take dydrogesterone 10 mg, 2 tablets twice daily from tenth day of menstruation for 15 days for 3-6 months.
Endometrial Biopsy (Pipelle) will be performed every 3-month to examine the endometrium.
All of the findings will be recorded.
|
At a dosage of 20 mg/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological complete response (CR) rates
Time Frame: From date of randomization until the date of CR, assessed up to 6 months
|
The CR rates will be calculated after 3 and 6-month therapy based on the following formula: (Number of participants who got CR)/(All enrolled participants).
The CR rates will be compared between two therapies (MPA VS dydrogesterone), also between two lesions (SH VS CH).
|
From date of randomization until the date of CR, assessed up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median time of pathological complete response (CR)
Time Frame: From date of randomization until the date of CR, assessed up to 6 months
|
Median time of histologic regression from endometrial hyperplasia without atypia to normal endometrium, and comparison will be performed between two treatments and two lesions (SH vs CH).
|
From date of randomization until the date of CR, assessed up to 6 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: up to 2 years after the treatment for each patient
|
Adverse events related with MPA (Medroxyprogesterone acetate ) or dydrogesterone include acne, irregular bleeding, breast tenderness, decreased scalp hair, difficulty falling or remaining asleep, stomach pain, and weight loss or gain, depression and mood changes. Severe side effects include thrombus and impaired liver and kidney function. The investigators will record any symptoms, evaluate the correlation and count the events. And comparison will be performed between two treatments and two lesions (SH vs CH). |
up to 2 years after the treatment for each patient
|
Relapse rates
Time Frame: up to 2 years after the treatment for each patient
|
All enrolled patients will be followed up for 2 years.
During the following-up period, if patients recur after complete regression, they will be counted and the number of recurrence will be divided by number of patients followed up, then we can get the relapse rates.Comparison will be performed between two treatments and two lesions (SH vs CH).
|
up to 2 years after the treatment for each patient
|
Rate of pregnancy
Time Frame: up to 2 years after the treatment for each patient
|
For patients have a desire for fertility, pregnancies, births and related outcomes will be counted, and the rate of pregnancy will be counted as number of pregnancies/ number of patients trying to fertility in the following period.
Comparison will be performed between two treatments and two lesions (SH vs CH).
|
up to 2 years after the treatment for each patient
|
Compliance
Time Frame: up to 2 years after the treatment for each patient
|
The investigators designed a questionnaire to evaluate the compliance through treatment.
Comparison will be performed between two treatments and two lesions (SH vs CH).
|
up to 2 years after the treatment for each patient
|
cost
Time Frame: From date of randomization until the date of CR, assessed up to 6 months
|
Treatment-related cost in each patient during the period beginning from randomization to the date of CR.Comparison will be performed between two treatments and two lesions (SH vs CH).
|
From date of randomization until the date of CR, assessed up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Xiaojun Chen, PhD, Obstetrics & Gynecology Hospital of Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Uterine Diseases
- Hyperplasia
- Endometrial Hyperplasia
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Progestins
- Contraceptive Agents, Male
- Dydrogesterone
- Medroxyprogesterone Acetate
- Medroxyprogesterone
Other Study ID Numbers
- 53201014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Hyperplasia Without Atypia
-
Kocaeli UniversityCompletedEndometrial Hyperplasia Without AtypiaTurkey
-
UNC Lineberger Comprehensive Cancer CenterCompletedEndometrial Hyperplasia | Endometrial Hyperplasia Without AtypiaUnited States
-
Pirogov Russian National Research Medical UniversityCompletedEndometrial Cancer | Endometrial Hyperplasia Without Atypia | Postmenopause | Peripheral Blood Mononuclear Cells | Endometrial Hyperplasia With Atypia | Estrogen Receptor | Progesterone Receptor
-
Regina Elena Cancer InstituteFondazione Policlinico Universitario Agostino Gemelli IRCCS; University of... and other collaboratorsActive, not recruitingBreast Cancer | Endometrial Cancer | Endometrial Hyperplasia With Atypia | TAMItaly
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedStage II Uterine Corpus Cancer | Stage IA Uterine Corpus Cancer | Stage IB Uterine Corpus Cancer | Complex Endometrial Hyperplasia With AtypiaUnited States
-
Queensland Centre for Gynaecological CancerThe University of Queensland; Queensland University of TechnologyActive, not recruitingComplex Endometrial Hyperplasia With Atypia | Grade 1 Endometrial Endometrioid AdenocarcinomaAustralia, New Zealand
-
Dana-Farber Cancer InstituteActive, not recruitingFlat Epithelia Atypia | Intraductal Papilloma Without AtypiaUnited States
-
Gloucestershire Hospitals NHS Foundation TrustSuspendedLichen Sclerosus | Squamous Cell Carcinoma | Normal Vulval Skin | High Grade Dysplasia - Usual Type ('VIN 2-3') | High Grade Dysplasia - Differentiated Type ('VIN 2-3') | Epithelial Hyperplasia Without Atypia | Atypia Not Otherwise Specified/ Low Grade Dysplasia ('VIN 1') | Pagets Disease of the...United Kingdom
-
Sohag UniversityNot yet recruitingEndometrial Cancer and Endometrial HyperplasiaEgypt
-
CHU de ReimsUnknownEndometrial Hyperplasia and Endometrial CancersFrance
Clinical Trials on Medroxyprogesterone Acetate
-
Women's Health Care Clinic, Torrance, CaliforniaCompletedDysfunctional Uterine BleedingUnited States
-
Turku University HospitalCompleted
-
Mahidol UniversityCompleted
-
Kaiser PermanenteTerminatedDysfunctional Uterine BleedingUnited States
-
University of Alabama at BirminghamMerck Sharp & Dohme LLC; University of Washington; Wits Reproductive Health and...Active, not recruitingHIV Infections | Contraception | Drug-drug InteractionSouth Africa
-
Chulalongkorn UniversityCompletedClinically Diagnosed Endometriotic Patient Was Defined as a Woman Who Has Pelvic Pain and at Least One Evidence of PV or TVS
-
Teva Pharmaceuticals USACompleted
-
Emory UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHormonal ContraceptionUnited States